Founded by a Nobel prize winner, Bicycle Therapeutics (BCYC) has developed a large amount of intangible assets, which should interest investors. Besides, the company reports collaboration agreements with larger pharmaceutical institutions, cash in hand, and no debt. While Bicycle is still at an early stage of development, new data is expected in the second half of 2019. Investors should review the preclinical results. If the results please the market, the share price could spike up.
Source: Prospectus
Source: Prospectus
Business, Platform And Product Candidates
Founded in 2009, Bicycle is a clinical-stage biopharmaceutical company